Patient and transplantation characteristics (N = 6028)
| Characteristic . | n (%) . |
|---|---|
| Follow-up of survivors, y | |
| Median | 7.8 |
| IQR | 5-11.1 |
| Range | <1 to 20 |
| Age at transplantation, y | |
| Median | 6 |
| IQR | 1-11 |
| Range | <1 to 20 |
| Sex | |
| Male | 3610 (60) |
| Female | 2418 (40) |
| Region of transplantation center | |
| United States | 3290 (55) |
| Canada | 195 (3) |
| Europe | 816 (13) |
| India and Asia | 307 (5) |
| Middle East and Africa | 697 (12) |
| Central and South America | 463 (8) |
| Australia and New Zealand | 251 (4) |
| Other | 9 (<1) |
| Year of transplantation | |
| 1995-1999 | 1763 (29) |
| 2000-2004 | 1803 (30) |
| 2005-2009 | 1977 (33) |
| 2010-2012 | 485 (8) |
| Primary disease category | |
| Bone marrow failure disorder | 2405 (40) |
| SAA | 1456 (24) |
| FA | 598 (10) |
| Other marrow failure | 351 (6) |
| Hemoglobinopathy | 874 (15) |
| Thalassemia | 574 (10) |
| SCD | 300 (5) |
| Immunodeficiency syndrome | 1415 (23) |
| SCID | 583 (10) |
| Non-SCID PID | 807 (13) |
| Histiocytic disorder | 469 (8) |
| Metabolic disease, leukodystrophy, other | 1334 (22) |
| Metabolic disorder | 476 (8) |
| Leukodystrophy | 227 (4) |
| Osteopetrosis | 150 (2) |
| Autoimmune disease | 25 (<1) |
| Other | 12 (<1) |
| Conditioning regimen | |
| None | 141 (2) |
| TBI + Cy ± other | 894 (15) |
| TBI + other | 117 (2) |
| Bu + Cy | 2720 (45) |
| Bu + other (not Cy) | 309 (5) |
| Cy + other (no Bu) | 1239 (21) |
| Fludarabine + other | 493 (8) |
| Other | 115 (2) |
| Graft type | |
| Bone marrow | 3922 (65) |
| Peripheral blood | 553 (9) |
| Cord blood | 1553 (26) |
| Donor | |
| HLA-identical sibling | 2298 (38) |
| Other related | 482 (8) |
| Unrelated | 1695 (28) |
| Cord blood | 1553 (26) |
| Characteristic . | n (%) . |
|---|---|
| Follow-up of survivors, y | |
| Median | 7.8 |
| IQR | 5-11.1 |
| Range | <1 to 20 |
| Age at transplantation, y | |
| Median | 6 |
| IQR | 1-11 |
| Range | <1 to 20 |
| Sex | |
| Male | 3610 (60) |
| Female | 2418 (40) |
| Region of transplantation center | |
| United States | 3290 (55) |
| Canada | 195 (3) |
| Europe | 816 (13) |
| India and Asia | 307 (5) |
| Middle East and Africa | 697 (12) |
| Central and South America | 463 (8) |
| Australia and New Zealand | 251 (4) |
| Other | 9 (<1) |
| Year of transplantation | |
| 1995-1999 | 1763 (29) |
| 2000-2004 | 1803 (30) |
| 2005-2009 | 1977 (33) |
| 2010-2012 | 485 (8) |
| Primary disease category | |
| Bone marrow failure disorder | 2405 (40) |
| SAA | 1456 (24) |
| FA | 598 (10) |
| Other marrow failure | 351 (6) |
| Hemoglobinopathy | 874 (15) |
| Thalassemia | 574 (10) |
| SCD | 300 (5) |
| Immunodeficiency syndrome | 1415 (23) |
| SCID | 583 (10) |
| Non-SCID PID | 807 (13) |
| Histiocytic disorder | 469 (8) |
| Metabolic disease, leukodystrophy, other | 1334 (22) |
| Metabolic disorder | 476 (8) |
| Leukodystrophy | 227 (4) |
| Osteopetrosis | 150 (2) |
| Autoimmune disease | 25 (<1) |
| Other | 12 (<1) |
| Conditioning regimen | |
| None | 141 (2) |
| TBI + Cy ± other | 894 (15) |
| TBI + other | 117 (2) |
| Bu + Cy | 2720 (45) |
| Bu + other (not Cy) | 309 (5) |
| Cy + other (no Bu) | 1239 (21) |
| Fludarabine + other | 493 (8) |
| Other | 115 (2) |
| Graft type | |
| Bone marrow | 3922 (65) |
| Peripheral blood | 553 (9) |
| Cord blood | 1553 (26) |
| Donor | |
| HLA-identical sibling | 2298 (38) |
| Other related | 482 (8) |
| Unrelated | 1695 (28) |
| Cord blood | 1553 (26) |
Bu, busulfan; Cy, cyclophosphamide; SCID, severe combined immunodeficiency.